France: Too Little, Too Late?
This article was originally published in Start Up
Executive Summary
This past December, industry leaders gathered in Paris for France Biotech's annual meeting to try to figure out why the sector has failed to show the same dynamism as those of its British and German neighbors. There wasn't a single biotech IPO in France last year, and even alliances were few and far between. Lack of large pharmaceutical companies, experienced management, and insufficient government support may partially explain the low level of deal activity.